Profiling Precursor Lipids for Specialized Pro-Resolution Molecules in Platelet-Rich Fibrin  Following Fish Oil and Aspirin Intake by McCormack, Danielle M
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2017 
Profiling Precursor Lipids for Specialized Pro-Resolution 
Molecules in Platelet-Rich Fibrin Following Fish Oil and Aspirin 
Intake 
Danielle M. McCormack 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Periodontics and Periodontology Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/4761 
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has 
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. 
For more information, please contact libcompass@vcu.edu. 
  
 
 
 
 
© Danielle M. McCormack         2017 
All Rights Reserved
  
Profiling Precursor Lipids for Specialized Pro-Resolution Molecules in Platelet-Rich Fibrin 
Following Fish Oil and Aspirin Intake 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Dentistry at Virginia Commonwealth University. 
 
 
By 
 
 
Danielle M. McCormack 
BS Florida State University, Tallahassee 2009, DDS Virginia Commonwealth University 2014 
,  
 
Director: Parthasarathy A. Madurantakam 
Assistant Professor, Department of General Practice 
School of Dentistry 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2017 
 ii
Acknowledgment 
 
 
I would like to thank my committee, Dr. Parth Madurantakam, Dr. Dayanjan Wijesinghe, Dr. 
Thomas Waldrop, and Dr. Al Best for their support and guidance with all aspects of this research 
project. I would also like to thank Kim Hollaway for her excellence in phlebotomy training. I 
would like to express my appreciation to both the VCU Graduate Periodontics department for 
funding and Salvin for their generous donation of equipment.  
  
 iii
Table of Contents 
	
List of Tables ................................................................................................................................. iv 
List of Figures ................................................................................................................................. v	
Abstract .......................................................................................................................................... vi	
Introduction ..................................................................................................................................... 1	
Materials and Methods .................................................................................................................... 8	
Results ........................................................................................................................................... 14	
Discussion ..................................................................................................................................... 16	
Conclusions ................................................................................................................................... 20	
References ..................................................................................................................................... 21	
Tables ............................................................................................................................................ 25	
Figures........................................................................................................................................... 32	
Appendices .................................................................................................................................... 40	
Vita ................................................................................................................................................ 52	
 iv
 
List of Tables 
 
Table 1. Differences between the four treatment groups .............................................................. 25	
Table 2. Aspirin and EFA effects ................................................................................................. 26	
Table 3. ANCOVA results, P-values for each Lipid .................................................................... 27	
 v
 
List of Figures 
Figure 1: Chronology of events in acute inflammation and its resolution. ................................... 32	
Figure 2: A Schematic showing the paradigm shift in the approach towards treating chronic 
unresolved inflammation including periodontitis. ......................................................... 33	
Figure 3: Transcellular biosynthesis of SPM during platelet-neutrophil interaction. ................... 34	
Figure 4: Table of SPM mediators. ............................................................................................... 35	
Figure 5: Essential fatty acid production and metabolism to form eicosanoid signaling molecules, 
some of which are pro-inflammatory and others pro-resolving..................................... 36	
Figure 6: A. Armamentarium for the PRF preparation with labeled tubes for sample collection. B 
is the centrifuge used for PRF preparation (Intra-Lock, FL) ......................................... 37	
Figure 7: Clinical steps involved in generating PRF. ................................................................... 38	
Figure 8: Flow chart of study protocol. ........................................................................................ 39	
 
  
 vi
Abstract 
 
 
 
PROFILING PRECURSOR LIPIDS FOR SPECIALIZED PRO-RESOLUTION MOLECULES 
IN PLATELET-RICH FIBRIN FOLLOWING FISH OIL AND ASPIRIN INTAKE  
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Background: Current research has demonstrated that aspirin and fish oil (EFA) increase plasma 
levels of specialized pro-resolution molecules (SPMs). This study investigates their effects on 
SPM precursor pools in platelet rich fibrin (PRF).  Methods: Twenty healthy volunteers were 
randomly assigned to take aspirin; EFA or aspirin and EFA. Four hours later, SPM precursor 
levels were quantified using combined Liquid Chromatography tandem mass spectrometry. The 
differences between the groups: Aspirin (yes or no), EFA (yes or no), were analyzed by 
ANCOVA, testing for group differences after covarying out the baseline value. Results: There 
were 4 significant interactions, 1 with an aspirin effect, 2 with an EFA effect, and 64 with no 
 vii
difference between the groups. The significant interaction effect was found for the following 
lipidome: LPE(20:4), LPI(16:1), LPI(18:1), and LPI(20:3). Aspirin decreased the LPG(16:4) 
levels,  and EFA decreased the LPE(22:5) and PG(16:0/18:0) lipidomes.  Conclusions:  Some 
SPM precursor pools in PRF were increased following supplementation.  
 
Keywords: Platelet-rich fibrin, specialized pro-resolution molecules, mass spectrometry, 
precursor lipids, EFA, aspirin. 
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Introduction 
 
Periodontal Disease is a chronic inflammatory disease: It is becoming increasingly clear that 
bacteria are necessary, but not always sufficient to produce disease (1) and the tissue destruction 
is a result of exaggerated host inflammatory response to the biofilm. In addition to being 
associated with a variety of systemic diseases, (2) chronic periodontitis is the most prevalent 
disease affecting almost half of the US adult population (3).  
Acute Inflammation and Its Resolution 
In response to injury or infection, the protective program of acute inflammation and its complete 
and timely resolution are critical for the restoration of tissue homeostasis. This highly 
coordinated and synergistic program combines the distinct actions of multiple cell types to 
achieve pathogen eradication and subsequent tissue repair. The acute inflammatory response can 
be divided into 2 general phases: initiation and resolution (4, 5). 
Initiation is marked by: 
a. Tissue edema resulting from increased blood flow and permeability of the 
microvasculature; processes that are mediated, in part, by lipid mediators (ie, leukotrienes 
and prostaglandins) and other vasoactive products (ie, histamine and bradykinin).  
b. Subsequently, polymorphonuclear neutrophils (PMN) migrate to the area to 
defend against microbial invasion. Drawn to the site of injury by chemical signals 
including proinflammatory lipid mediators, PMN traverse the vasculature through precise 
interactions with endothelial adhesion receptors and subsequently engulf and degrade 
pathogens within phagolysosomes. 
The resolution phase is already being enacted at this early point as: 
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a. The influx of PMN is halted at a level appropriate for the insult and is accompanied by 
their timely apoptosis. 
b. Monocytes subsequently infiltrate the tissue where they differentiate into macrophages 
that avidly respond to the so-called find-me and eat-me signals (ie, nucleotides and 
externalized phosphatidylserine) released or presented by apoptotic cells such as PMN. 
c. Uptake of apoptotic cells by macrophages (ie, efferocytosis) is an anti-inflammatory 
process associated with decreased production of inflammatory mediators, thus coupling 
the initiation of inflammation with its ultimate resolution.  
d. The timely clearance of microbes and apoptotic cells is required to prevent bystander 
tissue damage and to set the stage for tissue repair and regeneration, allowing for the 
return to homeostasis.  
e. Active clearance of apoptotic cells is a key defining feature of resolution, as failed 
clearance can lead to cellular necrosis and exacerbated inflammation beyond the initial 
insult, impeding tissue repair. 
Critical to progressing from initiation to resolution is the temporal switch in lipid 
mediators that are biosynthesized by leukocytes in the tissue, a process known as lipid mediator 
class switching (Figure 1). Interruption of this process at any point (ie, prolonged leukocyte 
recruitment and survival, impairments in apoptotic cell removal, and alterations in macrophage 
phenotype switching) could potentially lead to chronic inflammation with resultant tissue 
damage, excessive fibrosis, and loss of function (5, 6).   
Resolution of inflammation is an active, agonist-mediated, well-orchestrated return of 
tissue homeostasis. It is important to realize that anti-inflammation and resolution are completely 
independent mechanisms that affect the final outcome. While anti-inflammation is a 
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pharmacologic intervention, resolution is biologic pathways that restore tissue homeostasis. A 
growing body of research suggests that chronic inflammatory periodontal disease is at least 
involves a failure of resolution pathways to restore homeostasis. 
For several years, anti-inflammatory agents were used for prevention and management of 
inflammatory diseases. However anti-inflammation is not the same as resolution. Once the 
inflammatory response is initiated, a continuous cascade of events takes place during which the 
body attempts to eliminate invaders through proinflammatory actions of cells and their products. 
The symptoms of inflammation are relieved primarily due to catabolism of proinflammatory 
mediators.  
Recently, the possibility of using potent ‘resolution agonists’ to orchestrate the return of 
the tissue to homeostasis and rescue resolution deficits has been proposed and is promising 
(Figure 2). Existing data demonstrate that natural pathways of resolution can be used to limit 
inflammation and promote healing and regeneration with a minimal risk of side effects. Within 
this context, lipid mediators represent a paradigm change in the management of periodontal 
diseases (7).  
Platelets and Acute Inflammation:  
Platelets or thrombocytes are one of the important components of blood that play very important 
role in hemostasis, inflammation and regeneration. Normal platelet counts in whole blood are in 
the range of 150,000 to 400,000 per micro-liter. Autologous platelet concentrates (APC) are 
derived from patients' own blood and are processed to enrich the amount of platelets to at least 
1,000,000 per micro-liter. Such a high concentration of platelets is expected to be a potent source 
of endogenous peptide growth factors and cytokines like PDGF, IGF, VEGF and FGF that 
stimulate healing of bone and soft tissues (8).  
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In contrast to anti-inflammatory effects of growth factors, its resolution is orchestrated by 
a family of lipid molecules called specialized pro-resolving mediators (SPM) including lipoxins, 
resolvins, maresins and protectins (9),(10).  
Specialized Pro-resolving Mediators- Lipoxins and Resolvins:  
Lipoxins (LX): are trihydroxy-products derived from arachidonic acid (AA) through the 
cooperative interaction of diverse cell types in the inflammatory milieu- neutrophils, eosinophils, 
monocytes, platelets, and endothelial cells. The dense clustering of different cell types presents a 
unique situation for lipid handling. In contrast to the synthesis of protein mediators (ie, 
cytokines), lipid mediators can be produced along enzyme pathways that involve multiple cells, 
in a process known as transcellular biosynthesis (Figure 3).  Under the action of cytosolic 
phospholipase A, membrane AA is immediately secreted into the extracellular milieu, where it is 
taken up and used by nearby cells. In this way, the inflamed tissue becomes a specialized organ 
for lipid metabolism, producing the types and amounts of lipid mediators needed to promote or 
resolve inflammation. 
 There are two major routes of LX production from AA in humans.  The type of 
lipoxygenase that initiates AA oxygenation can distinguish these, and these are distributed 
differently by cell type.  The first pathway involves the insertion of molecular oxygen at C-5 by 
5-lipoxygenase (5-LO) in concert with the 5-LO activating protein (FLAP) to produce 5-
hydroperoxyeicosatetraenoic acid (5-HpETE), which is further metabolized by 5-LO to produce 
the intermediate, leukotriene A (LTA). This pathway is conducted solely by leukocytes, since the 
distribution of 5-LO is largely restricted to these cell types. LTA4 is readily transferred to 
adjacent cells, usually leading to its processing to other LTs (11). However, adherent platelets, 
via 12-LO, will convert LTA4, donated by leukocytes, to LXA4 and LXB4.  The second major 
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route of LX biosynthesis involves the initial conversion of AA to 15(S)-HpETE by 15-LO. 
Following secretion, 15(S)-HpETE is taken up by either neutrophils or monocytes and rapidly 
converted through a 5-LO/ FLAP dependent mechanism to LXA4 and LXB4.  
Resolvins (Rv) are endogenous chemical mediators that are biosynthesized from the major ω-3 
fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), denoted E series 
(RvE) and D series (RvD) resolvins, respectively. Like LX, Rv can be produced through 
transcellular cooperation, initiated by enzymes in epithelial cells and completed by adjacent 
leukocytes. Conceptually, the substrates EPA and DHA are released from membrane 
phospholipids, metabolized in a transcellular fashion, and secreted in amounts sufficient to 
reverse the course of inflammation. Ideally, this must happen throughout the inflamed tissue, at a 
time that appropriately follows the elimination of the insult, which caused the inflammation, 
continuing on to a return to homeostasis.  
ω-3 fatty acids, Aspirin and SPM: Epidemiological, clinical, and animal studies provide 
substantial support that the long chain ω-3 fatty acids from fish and fish oils, eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) improve outcomes associated with inflammation 
(Figure 4) (12). The mechanisms by which ω-3 fatty acids exert their protection are still 
emerging but likely include alterations in cell membrane composition and effects on gene 
expression and receptors regulating signaling. The anti-inflammatory actions of ω-3 fatty acids 
are, in part, related to reduce leukocyte-derived cytokine formation and modulation of eicosanoid 
synthesis (13) (Figure 5). As mentioned above, resolution of inflammation is accomplished by 
SPMs derived from EPA and DHA, known as E-series and D-series resolvins, respectively.  
Aspirin irreversibly acetylates cyclooxygenase-2 (COX-2), inhibiting its ability to produce 
prostanoids. However, acetylated COX-2 can metabolize AA to 15(R)-HETE, which may then 
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be processed to the “aspirin-triggered” LX by 5-LO. Thus, epimers of LXA4 and LXB4 can be 
produced following aspirin treatment. Similar to LX, aspirin-triggered Rv epimers are produced 
by the acetylated COX-2/5-LO pathway. 
 Clinical studies involving supplementation of omega-3 fatty acids and detection of SPM 
from human plasma samples using targeted liquid chromatography tandem mass spectrometry 
(LC-MS/MS) have showed that the plasma levels of SPMs can be accurately quantified using 
this technology and that these levels were increased within 4 hours of omega-3 and aspirin intake 
(9). In another recent study, healthy volunteers were given ω-3 fatty acid supplements for seven 
days and then randomized to receive aspirin or placebo in addition to ω-3 fatty acids during the 
last two days. The study showed that ω-3 fatty acid supplementation for five days increased 
plasma levels of 18-HEPE, 17-HDHA, 14-HDHA, and RvE1. Aspirin taken in addition to ω-3 
fatty acids did not differentially affect any SPM. However, aspirin significantly reduced the ratio 
of R- to S-isomers of 17-HDHA (14). 
 In a trial on 74 patients with chronic renal disease randomized to ω-3 fatty acids or 
coenzyme Q10 (CoQ) for eight weeks, it was found that ω-3 Fatty acids significantly increased 
plasma levels of 18-HEPE, 17-HDHA, and RvD1 while CoQ had no effect on any plasma SPM. 
Regression analysis showed the increase in 18-HEPE and 17-HDHA following ω-3 fatty acids 
was associated with a change in platelet EPA and DHA, respectively (15). 
Patients with metabolic syndrome who started with reduced plasma concentrations of the 
precursors of the E- and D- series resolvins had their plasma E-series resolvins increased 
following ω -3 fatty acid supplementation and the addition of aspirin did not alter any of the 
plasma SPMs in diseased and control subjects (16). 
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Autologous Platelet Concentrates:  Platelets or thrombocytes are one of the important 
components of blood that play very important role in hemostasis, inflammation and regeneration. 
Normal platelet counts in whole blood are in the range of 150,000 to 400,000 per micro-liter. 
The efficacy of platelets is due to degranulation of alpha and dense granules where a variety of 
growth factors responsible for regeneration is stored (17). Autologous platelet concentrates 
(APC) are derived from patients' own blood and are processed to enrich the amount of platelets 
to at least 1,000,000 per micro-liter.  
One form of autologous platelet concentrate is platelet-rich fibrin (PRF), which is a 
second-generation platelet concentrate that was developed in France by Choukroun that is being 
used routinely in clinical practice (18, 19).  The processing technique of PRF requires minimum 
amount of blood to be harvested (10 ml) and has some advantages compared to platelet-rich 
plasma (PRP) such as the simplified technique for preparation/application, minimal expense, and 
lack of biochemical modification (no anticoagulant or bovine thrombin is required). 
Considering the fact that platelet-rich fibrin (PRF) once applied is allowed to stay in contact with 
the wound surface and stimulate a slow release of growth factors for 7 days and up to 28 days in 
vitro (20, 21), it is important to know if the PRF has sufficient capacity to provide a continuous 
supply of precursors for the continuous production of SPMs. In this study, we seek to investigate 
the levels of precursors of SPM in PRF and the effect of administering essential fatty acid or 
aspirin on the total levels of the precursors of these signaling lipids.  
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Materials and Methods 
Protocol: 
The clinical study was undertaken after prior approved by the Institutional Review Board of 
Virginia Commonwealth University (Study ID: HM20002473). Informed consent was obtained 
from each participant. All experiments listed in this protocol involve handling of human blood 
and/or blood products and appropriate personal protective equipment need to be worn at all 
times. The waste were considered as biohazard and disposed of according to regulations. The 
protocol for the entire procedure is listed in the Appendix 1. 
Study Design:  
Sixty study participants were recruited who satisfy the following inclusion/exclusion criteria. 
Inclusion Criteria: 
1. Healthy adults (>18 years of age) 
2. Non-pregnant 
3. Weight > 110 pounds 
Exclusion Criteria: 
1. History of smoking in the past 2 years 
2. Individuals with known medical conditions and currently receiving treatment for the 
same 
3. History of anti-coagulant, immunosuppressive or antibiotic therapy in the last 6 months 
4. History of non-steroidal anti-inflammatory drug use (Advil, Tylenol) in the past 2 days 
or Aspirin in the past 10 days 
5. History of essential fatty acid (fish oil supplement) intake in the past month 
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6. Known allergic to fish oil components or nuts 
Once written informed consent was obtained from the participant, the subject opened a sealed 
envelope to determine the group he/she will fall into. The research coordinator assigned the 
subjects into any one of the four groups with 15 participants each:  
Group A: Control 
Group B: Subjects taking one softgel of fish oil supplement (1400 mg, Sundown Naturals, NY) 
Group C: Subjects taking one tablet of Bayer low-dose (81 mg) aspirin 
Group D: Subjects with both EFA supplement (1.4 g) and aspirin (81 mg) 2 hours apart 
Blood draw protocol:  
Each patient had a total of 2 blood draws and the initial draw was done to establish the baseline. 
After 4 hours after drug administration, the second blood draw was done. Personnel adequately 
trained in phlebotomy performed the blood draws. At each time, 10 ml of blood was collected in 
red top tubes and centrifuged in IntraSpin System (Intra-lock, FL) (Figure 6). The tubes were 
centrifuged at 2700 rpm for 12 minutes at room temperature. The PRF membrane was separated 
from the clot and was compressed using the Xpression Box for 30 sec (Figure 7). The PRF plugs 
were transferred to labeled tubes with participant’s ID number, age, and sex, to protect 
confidentiality. The labeled specimens were immediately stored at -80oC freezer to prevent 
degradation until ready for analysis. When all samples were collected, the samples were thawed 
and analyzed using the protocol described below.  
Sample preparation for lipid extraction: 
Lipids were extracted from the biological material using a modified Bligh and Dyer method (22). 
Briefly, to 200μl of PRP 1ml of methanol containing the required internal standards were added 
followed by the addition of 0.5 ml of chloroform. The monophasic mixture thus obtained was 
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incubated at 4oC overnight. Depending on the analysis carried out, the extracted lipids were 
either further purified using solid phase extraction or used as is following dilution to achieve the 
target concentration in the linear dynamic range.  
Lipid Quantification using LC-MS/MS: 
These specialized pro-resolving mediators were analyzed using targeted LC MS/MS methods 
using Shimadzu Nexera UPLC and a hybrid triple quadrupole linear ion trap (AB SCIEX 6500), 
or via untargeted analysis using either LC MS/MS or shotgun lipidomics (AB SCIEX 5600). The 
available lipid panel allowed quantification of following lipids: 
FFA(16:1) FFA(16:2) FFA(24:1) 
FFA(18:1)  FFA(18:2) FFA(18:3) 
FFA(20:0) FFA(20:1) FFA(20:3) 
FFA(20:4) FFA(20:5) FFA(22:4) 
FFA(22:5) FFA(22:6) FFA(24:0) 
LPC(14:0) +AcO LPC(16:1) +AcO LPC(16:0) +AcO 
LPC(18:0) +AcO LPC(18:1) +AcO LPC(18:2) +AcO 
LPC(18:3) +AcO LPC(20:0) +AcO LPC(20:1) +AcO 
LPC(20:2) +AcO LPC(20:3) +AcO LPC(20:4) +AcO 
LPC(20:5) +AcO LPC(22:4) +AcO LPC(22:5) +AcO 
LPC(22:6) +AcO LPE(16:0) LPE(16:1) 
LPE(18:0) LPE(18:1) LPE(18:2) 
LPE(18:3) LPE(20:0) LPE(20:1) 
LPE(20:2) LPE(20:3) LPE(20:4) 
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LPE(20:5) LPE(22:4) LPE(22:5) 
LPE(22:6) LPG(14:0) LPG(18:1) 
LPG(18:3) LPG(20:1) LPG(20:3) 
LPG(20:4) LPG(22:4) LPG(22:5) 
LPG(22:6) LPI(16:0) LPI(18:0) 
LPI(18:1) LPI(18:2) LPI(20:3) 
LPI(20:4) LPS(18:0) PE(18:2/20:1) 
PE(P-16:0/16:0) PS(18:2/22:6) SM(14:0) 
SM(16:0) SM(18:0) SM(18:1) 
SM(20:0) SM(20:1) SM(22:0) 
SM(22:1) SM(24:0) SM(24:1) 
SM(26:0) SM(26:1)  
 
where: 
SM=Sphingomyelin 
 
LPC=Lysophosphotidylcholine 
 
LPE=Lysophosphatidylethanolamine 
 
LPG=Lysophosphatidylglycerol 
 
LPI=Lysophosphotidylinositol 
 
LPS-Lysopphosphatidylserine 
 
PS=Phosphatidylserine 
 
FFA=Free Fatty Acids 
 
PE= Phosphatidylethanolamine 
 
  12
The number designation is for the following (XX:Y): 
XX=number of carbon atoms in the acyl chain. Also referred to as the chain length. 
Y=number of double bonds in the acyl chain. 
 
Statistical analysis: 
Participants were randomly assigned to one of four group intervention groups using a two-by-
two design (ETA=No or Yes and Aspirin=No or Yes) and there was a specimen collection at 
baseline and post-intervention. The statistical method used to analyze this question was an 
analysis of covariance (ANCOVA) with the following effects: Baseline covariate, Aspirin, EFA, 
and the EFA*Aspirin interaction. There are thus three questions of interest. 
 The p-value associated with the Aspirin effect answers this question: Is the post-
intervention mean of the Aspirin=No groups different than the post-intervention mean of 
the Aspirin=Yes groups, after covarying out the patients’ baseline? Question: Does 
Aspirin have a simple effect? 
 The p-value associated with the EFA effect answers this question: Is the post-intervention 
mean of the EFA=No groups different than the post-intervention mean of the EFA=Yes 
groups, after covarying out the patients’ baseline? Question: Does EFA have a simple 
effect? 
 The p-value associated with the EFA*Aspirin interaction answers this question: Does the 
effect of EFA differ in the Aspirin=No and Aspirin=Yes groups, after covarying out the 
patients’ baseline. Question: Is the effect of EFA and Aspirin complicated? 
In statistical analysis, the answer to the interaction question is inspected first. And so, the results 
will be reported according to the following patterns:  
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 4 Treatments: In those lipid precursors where there is a significant EFA*Aspirin 
interaction, all possible treatment group differences will be inspected by Tukey’s HSD 
multiple-comparison procedure and the differences summarized.   
 Aspirin: In those lipid precursors where there is no significant interaction, but there is a 
significant Aspirin effect, the two Aspirin groups will be compared. 
 EFA: In those lipid precursors where there is no significant interaction, but there is a 
significant EFA effect, the two EFA groups will be compared. 
 No effect: In those lipid precursors with no significant interaction effects and no 
significant main effects, the lipid precursors will be listed. 
All analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary 
NC). Statistical significance was declared at alpha = 0.05. (Unfortunately, in this small study) No 
correction for multiple comparisons was applied. 
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Results 
Flow of Participants  
For this study, 20 of the participant samples were available for analysis. There were 5 
participants in group A, 6 in group B, 4 in group C, and 5 in group D (Figure 8). 
Significant interactions  
There were 71 SPM screened in the 20 PRF subjects. There were 4 SPMs with a significant 
interaction, 1 with an Aspirin effect, 2 with an EFA effect, and 64 with no apparent difference 
between the groups. 
Interaction effect 
There was a significant interaction effect for these SPMs: LPE(20:4), LPI(16:1), LPI(18:1), and 
LPI(20:3). These results are shown in Table 1 where the means for the four treatment groups are 
ordered by size in the right-hand column. Means sharing the same superscript were not 
significantly different.  
The pattern that is evident for LPE(20:4) is that there is no significant EFA difference 
(P=0.061), no significant Aspirin difference (P=0.458) but a significant interaction (P=0.046). 
That is, there is some evidence for a difference between the four groups but the pattern is not 
simple. As may be seen by the fact that all four means share the same “a” superscript, the 
multiple comparison procedure cannot identify which of the groups were different. 
The pattern for LPI(16:1) is clearer. The EFA=No Aspirin=No group has a significantly 
higher mean LPI(16.:1) than any of the other three groups. 
The pattern for LPI(18:1) and LPI(20:3) is that the EFA=No Aspirin=NO group is only 
significantly higher than the EFA=No Aspirin=Yes group. And the other two groups were not 
different from any of the other groups. 
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Aspirin effect  
The only significant Aspirin effect was evident in LPG(16:1). 
EFA effect 
A significant EFA effect was evident in LPE(22:5) and PG(16:0/18:0). The Aspirin and EFA 
effects are shown in Table 2. For LPG(16:1) the no Aspirin group had higher levels than the 
Aspirin groups (a difference of -0.04, P=0.044). For LPE(22:5) the no EFA group had lower 
mean than the EFA group (a difference of 16.3, P=0.050). For PG(16:0/18:0) the no EFA groups 
had higher mean than the EFA group (a difference of -3.6, P=0.016). 
No effect evident  
There was no difference between the groups for these metabolomics: FFA(16:1), FFA(16:2), 
FFA(18:1), FFA(18:2), FFA(18:3), FFA(20:0), FFA(20:1), FFA(20:3), FFA(20:4), FFA(20:5), 
FFA(22:4), FFA(22:5), FFA(22:6), FFA(24:0), FFA(24:1), LPC(14:0) +AcO, LPC(16:0) +AcO, 
LPC(16:1) +AcO, LPC(18:0) +AcO, LPC(18:1) +AcO, LPC(18:2) +AcO, LPC(18:3) +AcO, 
LPC(20:0) +AcO, LPC(20:1) +AcO, LPC(20:2) +AcO, LPC(20:3) +AcO, LPC(20:4) +AcO, 
LPC(20:5) +AcO, LPC(22:4) +AcO, LPC(22:5) +AcO, LPC(22:6) +AcO, LPE(14:0), 
LPE(16:0), LPE(16:1), LPE(18:0), LPE(18:1), LPE(18:2), LPE(18:3), LPE(20:0), LPE(20:1), 
LPE(20:2), LPE(20:3), LPE(20:5), LPE(22:4), LPG(20:1), LPG(20:3), LPG(20:5), LPG(22:5), 
LPI(16:0), LPI(18:0), LPI(18:2), LPI(20:4), SM(14:0), SM(16:0), SM(18:0), SM(18:1), 
SM(20:0), SM(20:1), SM(22:0), SM(22:1), SM(24:0), SM(24:1), SM(26:0), and SM(26:1). 
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Discussion 
Acute inflammation is the body’s natural response to tissue injury and the failure to resolve 
inflammatory processes can lead to persistent low-grade inflammation. This chronic 
inflammation is associated with many diseases including periodontal disease, diabetes, 
rheumatoid arthritis, and inflammatory bowel disease (23). During periodontal surgery, soft 
tissue and bone augmentation procedures create acute tissue trauma and in turn trigger an 
inflammatory response. Immediate management of the wound site at time of surgery can 
improve both the healing process and patient’s postoperative pain. To help manage the acute 
inflammation that occurs after surgery, better knowledge of the active process of resolution of 
inflammation and healing are needed. 
There are many different cell types and signaling pathways involved in wound healing 
and it has been established over the past few decades that lipid signaling pathways play a 
dominant role (24). Serhan has shown that resolution of inflammation is not a passive process 
but an active one that is mediated by specialized pro-resolution molecules (SPMs) (25). SPM 
activity has been linked to cessation of polymorphonuclear leukocyte (PMN) recruitment to the 
wound site, and enhancement of macrophage uptake of debris, bacteria, and apoptotic cells to aid 
in inflammatory resolution and return to homeostasis. It has also been demonstrated that SPMs 
are increased in blood plasma and platelet concentrates with the intake of aspirin and essential 
fatty acids (EFA). This is due to increasing omega-3 fatty acids EPA and DHA triggering the 
“classical” pathway for SPM production as well as the “aspirin-trigger” pathway biosynthesis of 
specific epimers of these mediators. What is less understood are the lipid precursors along these 
pathways and whether manipulation of these precursors would provide a longer acting beneficial 
effect on wound healing.  
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Autologous platelet concentrates (APC) are currently being employed in the field of 
regenerative medicine because of the abundance of peptide growth factors and cytokines. 
Platelet-rich fibrin (PRF) brought about a huge advance in the evolution of platelet concentrates. 
Whereas platelet-rich plasma (PRP) undergoes rapid activation with the use of thrombin that can 
cause fibrinogen polymerization to be incomplete and result in friable fibrin gels, PRF forms a 
dense fibrin membrane with entrapped platelets that allows the slow release of growth factors 
over a longer period of time (19, 20, 26). The preparation of L-PRF allows for the processes of 
fibrinogen polymerization, platelet enhancement, and activation to occur simultaneously in one 
tube without the use of anticoagulant, bovine thrombin, or calcium chloride. This method of 
concentrating platelets not only simplifies the process when compared to PRP, but also 
significantly decreases costs. One important consideration in generating consistent L-PRF 
membranes is the speed of blood collection and immediate centrifugation of tubes, typically 
within a minute. If either harvesting of blood or transfer to centrifuge is prolonged, then the 
result is formation of a small incoherent, friable mass of fibrin with unknown content. Once the 
PRF clot is formed, it can be compressed into membranes and/or plugs to be utilized for surgical 
application.  
Although aspirin and fish oil have been shown to increase the levels of SPMs when 
examined in both whole blood and platelet concentrates, the levels of their lipid precursor 
molecules have never been investigated before now. Considering that PRF is able to stimulate a 
slow release of growth factors, it is important to know if the PRF has sufficient capacity to 
provide a continuous supply of precursors for the continuous production of SPMs and if 
administering essential fatty acid or aspirin has an effect on the total levels of the precursors of 
these bioactive lipids.  
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In this pilot study, lipids were measured in multiple forms that can be precursors to 
SPMs. Whereas free fatty acids may be used as immediate precursors, lysophospholipids are 
stored precursors that need an enzyme to be activated prior to potential SPM conversion. This 
stored form of lipid precursors has the potential to be cleaved and increase the available free fatty 
acids to be used as an immediate source for potential conversion to SPMs. The data presented in 
this experiment includes a population of 20 healthy adult participants.  Seventy-one lipid 
precursor molecules were quantified by analyzing platelet-rich fibrin plugs, by means of liquid 
chromatography mass spectrometry.  We found four lipid precursors with significant interactions 
when both aspirin and EFA were administered, one with an Aspirin effect, and two with a 
significant EFA effect. 
A significant interaction effect for LPE(20:4), LPI(16:1), LPI(18:1), and LPI(20:3) are 
shown in Table 1. LPE(20:4) is derived from a phosphatidylethanolamine, which is typical of 
cell membranes. This lipid precursor was seen to have a significant interaction when taking both 
aspirin and fish oil (P=0.046) but only a pattern towards significance when comparing mean 
values. The physiological significance of human plasma LPE remains unknown (15). The higher 
average of molecule LPI (16:1), LPI(18:1), and LPI(20:3) in the control groups compared to the 
groups receiving an intervention, indicates an overall increase in their metabolism with 
treatment. Both LPE and LPI are lysophospholipids derived from phospholipids, which are 
bioactive lipid molecules that make act as signaling mediators. In order to understand what 
signaling effects these lysophospholipids are contributing to, it would be necessary to know what 
free fatty acid chain was cleaved to contribute to either proinflammatory or anti-inflammatory 
pathways and would need further analysis. 
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The only significant Aspirin effect was evident in LPG(16:1), in which LPG is a 
precursor for synthesis of phosphatidylglycerol (PG). A significant EFA effect was evident in 
LPE(22:5) and PG(16:0/18:0). The increase in LPE(22:5) is noteworthy and has never been 
reported before and may indicate an increased metabolism of arachidonic acid to a longer chain 
omega-6 docosapentaenoic acid that does not give rise to inflammatory lipids. It can also 
indicate a buildup of precursor lipid omega-3 docosapentaenoic acid, for conversion to DHA, 
which is a precursor for SPM. Either way, this leads to a decrease in inflammation. Additional 
studies using flux analysis are needed to understand the exact mechanism. 
The most notable limitations of this study are the sample size taken to perform the pilot 
study and not having the ability to analyze all samples taken. This was due to having limited 
available access to liquid chromatography tandem mass spectrometry equipment.  Lipid 
precursors may have also been available in the supernatant that was compressed from the PRF 
plug and was not included in this pilot study analysis. Another limitation may be due to only 
giving a single dose of aspirin or fish oil. It is possible that more lipid precursors did not have a 
significant change due to the dose and time examined. It may be anticipated that a higher dose 
administered over a longer timeframe would show a change in these precursor pools. 
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Conclusions 
 
In this pilot study, findings indicate that the pattern for LPI(16:1) for EFA=No, Aspirin=No 
group has a significantly higher mean LPI(16:1) than any of the other three groups. This 
indicates a higher average of molecule LPI (16:1) in the control group compared to the groups 
receiving an intervention, indicating a metabolism of this molecule during treatment. 
The pattern for LPI(18:1) and LPI(20:3) is that the EFA=No, Aspirin=No group is only 
significantly higher than the EFA=No, Aspirin=Yes group. This also demonstrates higher levels 
LPI(18:1) and LPI(20:3) in the control group than compared to the aspirin group and again 
indicates an overall increase in their metabolism with treatment. The decrease in LPI with these 
treatments have never been reported before and is worth investigating further due to their 
signaling potential. 
The increase in LPE(22:5) is noteworthy and has never been reported before. It may 
indicate an increased metabolism of arachidonic acid to a longer chain omega-6 docosapentaenoic 
acid that does not give rise to inflammatory lipids. It can also indicate a build up of precursor lipid 
omega-3 docosapentaenoic acid, for conversion to DHA, which is a precursor for SPM. Either 
way, this leads to a decrease in inflammation. Additional studies using flux analysis are needed to 
understand the exact mechanism. 
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Tables 
Table 1. Differences between the four treatment groups 
 
Lipid Effects EFA Aspirin Mean  
LPE(20:4) EFA P=0.061 Yes Yes 436.36 a 
 
Aspirin P=0.458 No No 240.44 a 
 
EFA*Aspirin P=0.046 Yes No 226.08 a 
  
No Yes 138.57 a 
LPI(16:1) EFA P=0.038 No No 0.59 a 
 
Aspirin P=0.006 Yes No 0.26 b 
 
EFA*Aspirin P=0.014 Yes Yes 0.22 b 
  
No Yes 0.18 b 
LPI(18:1) EFA P=0.833 No No 9.74 a 
 
Aspirin P=0.016 Yes No 7.16 ba 
 
EFA*Aspirin P=0.026 Yes Yes 6.94 ba 
  
No Yes 4.78 b 
LPI(20:3) EFA P=0.349 No No 1.94 a 
 
Aspirin P=0.037 Yes Yes 1.63 ba 
 
EFA*Aspirin P=0.010 Yes No 1.49 ba 
    No Yes 0.73 b 
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Table 2. Aspirin and EFA effects 
 
Lipid Difference Means 
 
Aspirin effects 
LPG(16:1) -0.041 (-0.081 to -0.001) 0.134 no Aspirin 
 
P=0.044 0.093 Aspirin  
  
0.105 Baseline 
  EFA effects 
LPE(22:5) 16.390 (0.006 to 32.775) 19.852 no EFA 
 
P=0.050 36.242 EFA 
  
22.976 Baseline 
PG(16:0/18:0) -3.633 (-6.493 to -0.774) 6.212 no EFA 
 
P=0.016 2.579 EFA 
    3.738 Baseline 
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Table 3. ANCOVA results, P-values for each Lipid 
 
Lipid Aspirin EFA EFA*
Aspirin
Pre
FFA(16:1) 0.1134 0.2765 0.8483 0.7883
FFA(16:2) 0.2280 0.2148 0.8151 0.0313
FFA(18:1) 0.7327 0.6863 0.0779 0.1488
FFA(18:2) 0.2949 0.0604 0.3193 0.0005
FFA(18:3) 0.9411 0.7432 0.8723 0.7994
FFA(20:0) 0.0558 0.2681 0.3967 0.0697
FFA(20:1) 0.3146 0.7453 0.2332 0.0006
FFA(20:3) 0.5031 0.3891 0.1483 0.0063
FFA(20:4) 0.6229 0.9564 0.7267 0.5921
FFA(20:5) 0.7321 0.7588 0.5490 0.2683
FFA(22:4) 0.4904 0.9009 0.4384 0.1746
FFA(22:5) 0.2601 0.6193 0.0623 0.0901
FFA(22:6) 0.4266 0.7917 0.3351 0.4565
FFA(24:0) 0.4990 0.4600 0.2452 0.1853
FFA(24:1) 0.3082 0.6190 0.4226 0.0188
LPC(14:0) +AcO 0.7961 0.6492 0.4487 0.5090
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Lipid Aspirin EFA EFA*
Aspirin
Pre
LPC(16:0) +AcO 0.5781 0.5480 0.4745 0.9894
LPC(16:1) +AcO 0.4578 0.9997 0.2303 0.9529
LPC(18:0) +AcO 0.3074 0.5937 0.7867 0.3154
LPC(18:1) +AcO 0.9721 0.5483 0.1992 0.4134
LPC(18:2) +AcO 0.5063 0.9930 0.5849 0.6353
LPC(18:3) +AcO 0.6026 0.5640 0.2827 0.0296
LPC(20:0) +AcO 0.3275 0.3352 0.4722 0.2388
LPC(20:1) +AcO 0.8535 0.5375 0.3874 0.2317
LPC(20:2) +AcO 0.8742 0.5972 0.3778 0.4174
LPC(20:3) +AcO 0.4859 0.5306 0.2163 0.0850
LPC(20:4) +AcO 0.9823 0.9258 0.5881 0.4450
LPC(20:5) +AcO 0.4735 0.3225 0.1444 0.0010
LPC(22:4) +AcO 0.7142 0.7474 0.7388 0.2624
LPC(22:5) +AcO 0.2108 0.6177 0.3307 0.1974
LPC(22:6) +AcO 0.4761 0.9833 0.3732 0.0506
LPE(14:0) 0.1793 0.3970 0.2428 0.0669
LPE(16:0) 0.7005 0.2076 0.0942 0.9935
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Lipid Aspirin EFA EFA*
Aspirin
Pre
LPE(16:1) 0.2777 0.2778 0.3036 0.6181
LPE(18:0) 0.8110 0.3866 0.3843 0.6836
LPE(18:1) 0.3142 0.7656 0.1856 0.3545
LPE(18:2) 0.6997 0.4158 0.2101 0.2262
LPE(18:3) 0.9577 0.8959 0.7692 0.7763
LPE(20:0) 0.9550 0.3013 0.2697 0.4460
LPE(20:1) 0.5246 0.2362 0.1532 0.9159
LPE(20:2) 0.3787 0.0923 0.2240 0.1346
LPE(20:3) 0.8393 0.1124 0.1362 0.9534
LPE(20:4) 0.4584 0.0610 0.0464 0.1909
LPE(20:5) 0.3790 0.0750 0.2625 0.4191
LPE(22:4) 0.4239 0.1201 0.1075 0.2690
LPE(22:5) 0.3420 0.0499 0.1061 0.5516
LPG(16:1) 0.0438 0.4291 0.6619 0.5802
LPG(20:1) 0.8288 0.8144 0.4608 0.7720
LPG(20:3) 0.0733 0.7316 0.1516 0.0023
LPG(20:5) 0.1938 0.0972 0.4038 0.0521
  30
Lipid Aspirin EFA EFA*
Aspirin
Pre
LPG(22:5) 0.9600 0.3974 0.9015 0.8531
LPI(16:0) 0.4146 0.1875 0.1078 0.6380
LPI(16:1) 0.0058 0.0380 0.0139 0.4214
LPI(18:0) 0.2808 0.2564 0.7044 0.9164
LPI(18:1) 0.0158 0.8329 0.0261 0.9410
LPI(18:2) 0.2211 0.2269 0.1281 0.0385
LPI(20:3) 0.0365 0.3494 0.0105 0.1140
LPI(20:4) 0.0801 0.5070 0.1423 0.0959
PG(16:0/18:0) 0.3901 0.0164 0.5864 0.2215
SM(14:0) 0.5624 0.6177 0.4243 0.1714
SM(16:0) 0.4958 0.4171 0.4737 0.9161
SM(18:0) 0.7107 0.5754 0.3900 0.3132
SM(18:1) 0.7436 0.4500 0.4113 0.1881
SM(20:0) 0.8712 0.5778 0.4134 0.3613
SM(20:1) 0.9408 0.5706 0.4484 0.0758
SM(22:0) 0.6240 0.3385 0.6077 0.7652
SM(22:1) 0.8315 0.5123 0.5410 0.3200
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Lipid Aspirin EFA EFA*
Aspirin
Pre
SM(24:0) 0.4012 0.3135 0.5452 0.6122
SM(24:1) 0.6555 0.3851 0.2425 0.8221
SM(26:0) 0.4039 0.3545 0.4777 0.4562
SM(26:1) 0.5139 0.3585 0.2838 0.6842
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Figures 
 
Figure 1: Chronology of events in acute inflammation and its resolution.  
Source:  Adapted from Circulation Research. 2016;119:113-130 
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Figure 2: A Schematic showing the paradigm shift in the approach towards treating 
chronic unresolved inflammation including periodontitis.  
Source: http://www.eumbrella.org/timer_objectives.html 
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Figure 3: Transcellular biosynthesis of SPM during platelet-neutrophil interaction.  
Source: Levy G, Serhan C. Resolution and regulation of inflammation. Pathobiology of human 
disease. 2014;332-348  
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Figure 4: Table of SPM mediators.  
Source: Serhan C. Novel lipid mediators and resolution mechanisms in acute inflammation: To 
resolve or not? Am J Pathol. 2010 Oct;177(4):1576-1591 
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Figure 5: Essential fatty acid production and metabolism to form eicosanoid signaling 
molecules, some of which are pro-inflammatory and others pro-resolving.  
Source: https://en.wikipedia.org/wiki/Eicosanoid 
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Figure 6: A. Armamentarium for the PRF preparation with labeled tubes for sample 
collection. B is the centrifuge used for PRF preparation (Intra-Lock, FL) 
Source: http://www.dentalimplants.clinic/services/surgical-procedures 
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Figure 7: Clinical steps involved in generating PRF.  
A: Blood draw; B: Different layers of PRF in a tube; C: Preparing the membrane to form a 
plug; D: Compressed plug ready for storage. 
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Figure 8: Flow chart of study protocol.  
  40
 
Appendices 
Appendix 1: Chair-side PRF Research Protocol 
Before blood draw 
 
1. Prepare the materials basket which should include: a phlebotomy kit, goggles, 6 pre-
labeled PRP tubes, 3 pre-labeled PRF tubes, 3 5 mL syringes, goggles, 1 stopcock, 1 
blood needle, 3 1 mL syringes with needles, ascorbic acid, calcium chloride, thrombin, 
and 5 glass vials with labels 
2. Use a 5 mL syringe to draw 5 mL of calcium chloride and inject into the thrombin vial. 
Mix and let it sit until ready to use 
3. Load 0.5 mL of ascorbic into a 1 mL syringe 
4. Load 0.5 mL of the calcium chloride and thrombin mixture into the 2 other 1 mL syringes 
and leave for use after obtaining the blood samples 
5. Meet with the subject and have them fill out the screening form 
6. If the subject is eligible, review the participant consent form with the subject and if they 
wish to participate in the study have he/she sign the consent form with you as witness 
7. Write the subjects name onto the data sheet and let them know if they are in group A, B, 
C or D 
8. Inform the subject how to take their medication accordingly 
9. Ask the subject if they are ready for the blood draw or if they would like to schedule for 
another day 
  41
During the blood draw 
1. Bring out the phlebotomy kit which should include: 1 butterfly needle, 6 pre-labeled PRP 
tubes, 3 pre-labeled PRF tubes, gauze, 1 band aid, 1 test tube rack, 1 tourniquet, and 1 
alcohol swab. 
2. Put on gloves and goggles and ask the patient which arm they prefer to get the blood 
drawn from 
3. Wrap the tourniquet tightly around their desired arm and locate the vein you wish to use.  
4. Disinfect the area using the alcohol swab and allow 30 seconds for the area to dry. 
5. Proceed to inject the butterfly needle and draw 8 mL of blood into each PRF tube. 
6. Mix the contents of each tube by inverting the tube 5-8 times then place each tube on the 
rack 
7. Remove the tourniquet and place some gauze on the injected area, before removing the 
butterfly needle 
8. Apply pressure with the gauze until the bleeding has stopped or apply a band aid 
9. Thank and discharge the patient, confirming that they will be returning in 4-6 hours 
10. Clean/disinfect the patient area 
After the blood draw 
1. Place 1 of the PRF tubes labeled whole blood into the freezer for storage. Place the 
remaining two PRF tubes in opposite sides of the PRF centrifuge. 
2. Press the green button and centrifuge for 12 minutes 
3. Remove the 2 PRF tubes from the PRF centrifuge 
4. Place them onto a clean tray and bring out the Xpression kit which should include a tray, 
weight, small dish, scalpel, and tweezers. 
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5. Use tweezers to remove the PRF layer from each of the tubes and place them on the 
Xpression tray. Make sure the PRF layers are directly above the small dish. 
6. Use a scalpel to remove the red blood cells. 
7. Place the weight on top of the PRF layers for 30 seconds. 
8. Collect the PRF pellets and place them into separate labeled vials and then collect the 
liquid that is now in the small dish and transfer it into a separate labeled vial. 
9. Store all 3 samples into the freezer 
10. Clean and disinfect the area. 
11. Repeat the protocol when the patient arrives 4-6 hours later. 
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Appendix 2: Study key for preparation of PRF before medication taken and 4 hours after 
medication taken.  
Color code for preparation tubes: 
1. WHITE: Serum collected after blood clotted w/o centrifuging 
2. 2 GREEN PRF PLUG: PRF plug collected after centrifuging and excision 
3. BLUE PRF SN: Supernatant collected after PRF plug was made 
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Appendix 3: Recruitment Flyer 
Virginia Commonwealth University 
Healthy Volunteers Wanted for a Research Study 
Effects of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized Pro-resolving 
Lipid Mediators in Autologous Platelet Concentrate Gels 
 
The purpose of this research is to investigate the effects of two commonly available medications: 
fish-oil supplement and baby aspirin, on certain lipid (fat) components of blood necessary for 
wound healing. We will use sophisticated lab methods to accurately measure the blood levels of 
these fats in healthy volunteers after taking EFA (fish-oil pill) and baby aspirin. The information 
from this research will allow us to determine if taking either fish-oil or baby aspirin or both will 
have beneficial effects on wound healing following surgery. The research is conducted under the 
direction of Dr. Parthasarathy Madurantakam, Philips Institute of Oral Health Research, VCU 
School of Dentistry. 
 
The study will comprise of 60 participants and will involve two blood draws (60 ml each, 
approximately 4 tbsp) following clinically approved protocols, 4 hours apart. Your participation 
in this study will be limited to one half day and you will not be compensated for your 
participation.   
 
To be eligible, you should be a healthy adult (> 18 years of age and not having any known 
medical condition), non-pregnant and weigh at least 110 lbs. In addition, you will not be eligible 
to participate if you have: 
 
 History of smoking in the past 2 years 
 History of anti-coagulant, immunosuppresive or antibiotic therapy in the last 6 months 
 History of non-steroidal anti-inflammatory drug use (Advil, Tylenol or Aspirin) in the 
past 1 month 
 History of fish-oil supplement (essential fatty acid) intake in the past month 
 Known allergy to fish-oil components or nuts 
 
If you are interested and want to participate in this study or if you have any questions, please 
contact 
 
Kimberly Hollaway at klhollaway@vcu.edu or 804-828-4553 
Dr. Madurantakam at madurantakap@vcu.edu or 804-828-9353 
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Appendix 4: IRB approval and Consent form 
This Box for IRB Office Use Only – Do Not Delete or ReviseTemplate Rev Date: 6-19-14  
RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM TITLE: Effects 
of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized  
Pro-resolving Lipid Mediators in Saliva and Autologous Platelet Concentrate Gels  
VCU IRB PROTOCOL NUMBER: HM20002473 INVESTIGATOR: Dr. Parthasarathy 
Madurantakam  
You have been approached by the study doctor or the study staff because you have responded to 
our request to volunteer in the above-mentioned study. If any information in this consent 
document is not clear to you, please feel free to talk to the doctor or the staff involved in the 
study. You may take home an unsigned copy of this consent form to think about or discuss with 
family or friends before making your decision.  
In this consent form, “you” always refers to the research participant.  
PURPOSE OF THE STUDY  
The purpose of this research is to investigate the effects of two commonly available medications: 
fish-oil supplement and baby aspirin, on certain components in blood and saliva necessary for 
wound healing. The information from this research will allow us to determine if taking either 
fish-oil or baby aspirin or both has a beneficial effect on wound healing following surgical 
procedures.  
DESCRIPTION OF THE STUDY  
It has been recently found that presence of adequate amounts of certain kind of fats is critical for 
normal healing after surgery or trauma. Studying the blood levels of these fats was not possible 
because precision instruments were not available. We will use the recent technological advances 
to accurately measure the blood levels of these fats in healthy volunteers after taking EFA (fish-
oil pill) and baby aspirin. In addition, we will explore the potential of using saliva as an alternate 
body fluid to blood to detect these fats.  
Your participation will be limited to one day and we expect to enroll 60 study participants.  
PROCEDURES  
On the day of your scheduled appointment, a member of the research team will meet with you to 
go over the details of the study and the informed consent process. You can use this opportunity 
to ask any questions related to the study; seek more time to decide or may choose to not 
participate in the study.  
Once you sign the informed consent document, you will have the two procedures done:1. We 
will collect 4 ml of your saliva (that is normally secreted, unstimulated) into a  
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plastic tube2. A trained professional will draw 60 ml of your blood (4 tablespoons). This 
amount is  
well within the established safety limits.After the blood draw procedure, you will open a sealed 
envelope to determine which group you would belong. The study has 4 groups based on the type 
of medications the participants will take:  
Group A will not take any pills  
Group B will take one softgel of fish oil supplement (1400 mg, Sundown Naturals, NY) and a 
second blood draw 4 hours later  
Group C will take one tablet of Bayer low-dose (81 mg) aspirin and a second blood draw 4 hours 
later  
Group D will take fish-oil supplement first, low-dose aspirin 2 hours later and a second blood 
draw 2 hours later  
All your saliva and blood samples (baseline and at 4 hours) will be collected in a container that 
contains your study ID number, age, sex and the timing of blood draw (time 0 or time 4hrs). No 
personally identifiable information will be attached to the specimen and no one working in the 
laboratory will know the source.  
RISKS AND DISCOMFORTS  
There are no known risks of saliva collection other than the possibility of you experiencing mild 
discomfort due to dryness of the mouth.  
Possible side effects associated with having blood drawn may involve:  
     Headache  
     Bruising and discoloration at the site  
     Pain  
     Dizziness  
     Prolonged bleeding  
Currently, there is no evidence that aspirin and fish-oil interact to produce any complications. 
 BENEFITS TO YOU AND OTHERS  This is not a treatment study, and you are not 
expected to receive any direct benefits from your participation in the study. The information 
from this research study may lead to better treatment in the future for people who undergo 
surgery.  PAYMENT FOR PARTICIPATION  In order to compensate for your time and 
procedures you are going through, we will pay you a total sum of $30 by cash. This money will 
be paid at the end of second blood draw and saliva collection. No compensation will be provided 
if you do not come back for the second appointment. In such circumstance, you will no longer be 
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considered a study participant and your previously collected sample will not be used in the 
analysis.  ALTERNATIVE  Your alternative is not to participate in the study.   
 
CONFIDENTIALITY  
Potentially identifiable information about you will consist of names, email addresses and phone 
numbers. The investigator, research coordinator and the residents who work on this study will 
have access to this information. At the end of the blood draw procedure, the blood will be 
transferred into a separate container and labeled with a study ID number, your age, sex and the 
time of sample collection (time 0 or time 4 hours). No personally identifiable information will be 
attached to the specimen and hence no one working with the specimen in the laboratory will 
know the source.  
The research coordinator will store your identifiable information and link it to the study ID 
number. This information will be kept separately in a locked research area and only the 
coordinator and the PI will have access to this information. The personal identifiable information 
and the study code will be destroyed at the end of the study while the consent forms will be kept 
for a period of five years from the conclusion of the study in accordance to VCU policies.  
Although results of this research may be presented at meetings or in publications, identifiable 
personal information pertaining to participants will not be disclosed.  
QUESTIONS  
If you have any questions, complaints, or concerns about your participation in this research, 
contact:  
Dr. Parthasarathy Madurantakam  
Assistant ProfessorPhilips Institute, Room 41301101 East Leigh Street, Richmond, VA 
23298 Telephone: (804) 828 9353Email: madurantakap@vcu.edu  
and/or  
Ms. Kimberly Hollaway  
Research Coordinator521 North 11th Street, Richmond, Virginia 23298 Phone: (804) 828-
4553Email: klhollaway@vcu.edu  
The researcher/study staff named above is the best person(s) to call for questions about your 
participation in this study.  
If you have general questions about your rights as a participant in this or any other research, you 
may contact:  
Office of ResearchVirginia Commonwealth University 800 East Leigh Street, Suite 3000 P.O. 
Box 980568Richmond, VA 23298Telephone: (804) 827-2157  
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Contact this number for general questions, concerns, or complaints about research. You may also 
call this number if you cannot reach the research team or if you wish to talk to someone else. 
General information about participation in research studies can also be found at 
http://www.research.vcu.edu/irb/volunteers.htm.  
Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions.  
CONSENT  
I have been provided with an opportunity to read this consent form carefully. All of the questions 
that I wish to raise concerning this study have been answered.  
By signing this consent form, I have not waived any of the legal rights or benefits, to which I 
otherwise would be entitled. My signature indicates that I freely consent to participate in this 
research study. I will receive a copy of the consent form once I have agreed to participate.  
Participant Name, printed  
Participant Signature Date  
Name of Person Conducting Informed Consent Date Discussion / Witness  
Signature of Person Conducting Informed Consent Date Discussion / Witness  
Principal Investigator Signature (if different from above) Date  
Approved by the VCU IRB on 5/4/2015  
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Appendix 5: Aspirin Regimen- Bayer® Low Dose Aspirin 81 mg insert 
 
 
8  
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Appendix 6: Brand of fish oil used in the study 
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Appendix 7: Recruitment Flyer 
Virginia Commonwealth University 
Healthy Volunteers Wanted for a Research Study 
Effects of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized Pro-resolving 
Lipid Mediators in Autologous Platelet Concentrate Gels 
The purpose of this research is to investigate the effects of two commonly available medications: 
fish-oil supplement and baby aspirin, on certain lipid (fat) components of blood necessary for 
wound healing. We will use sophisticated lab methods to accurately measure the blood levels of 
these fats in healthy volunteers after taking EFA (fish-oil pill) and baby aspirin. The information 
from this research will allow us to determine if taking either fish-oil or baby aspirin or both will 
have beneficial effects on wound healing following surgery. The research is conducted under the 
direction of Dr. Parthasarathy Madurantakam, Philips Institute of Oral Health Research, VCU 
School of Dentistry. 
The study will comprise of 60 participants and will involve two blood draws (60 ml each, 
approximately 4 tbsp) following clinically approved protocols, 4 hours apart. Your participation 
in this study will be limited to one half day and you will not be compensated for your 
participation.   
To be eligible, you should be a healthy adult (> 18 years of age and not having any known 
medical condition), non-pregnant and weigh at least 110 lbs. In addition, you will not be eligible 
to participate if you have: 
● History of smoking in the past 2 years 
● History of anti-coagulant, immunosuppresive or antibiotic therapy in the last 6 months 
● History of non-steroidal anti-inflammatory drug use (Advil, Tylenol or Aspirin) in the 
past 1 month 
● History of fish-oil supplement (essential fatty acid) intake in the past month 
● Known allergy to fish-oil components or nuts 
If you are interested and want to participate in this study or if you have any questions, please 
contact  
Kimberly Hollaway at klhollaway@vcu.edu or 804-828-4553 
Dr. Madurantakam at madurantakap@vcu.edu or 804-828-9353 
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Dr. Danielle McCormack was born in Miami, Florida, and grew up in Port Charlotte, Florida. 
She received a Bachelor of Science in Biology from Florida State University in 2009 before 
attending Virginia Commonwealth University School of Dentistry, where she earned a Doctor of 
Dental Surgery in 2014. She is a member of the American Dental Association, Virginia Dental 
Association, and the American Academy of Periodontology. Dr. McCormack will graduate from 
Virginia Commonwealth University with a Master of Science in Dentistry, and a Specialty 
Certificate in Periodontics.  
